Thermo Fisher Scientific Inc. (NYSE:TMO) Receives $633.68 Consensus PT from Brokerages

Thermo Fisher Scientific Inc. (NYSE:TMO) has been given an average recommendation of “Moderate Buy” by the twenty-one research firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, eighteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $633.6842.

TMO has been the subject of a number of research analyst reports. TD Cowen lowered their target price on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a research note on Friday, January 30th. Barclays increased their price objective on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, January 30th. Evercore restated an “outperform” rating and set a $650.00 target price on shares of Thermo Fisher Scientific in a report on Monday, January 5th. UBS Group reiterated a “neutral” rating and issued a $615.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Finally, The Goldman Sachs Group started coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, December 9th. They set a “buy” rating and a $685.00 price target for the company.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the completion of the transaction, the executive vice president owned 20,752 shares of the company’s stock, valued at $11,230,982.40. The trade was a 1.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.33% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

A number of institutional investors have recently made changes to their positions in the company. Howard Capital Management Inc. raised its holdings in Thermo Fisher Scientific by 0.5% in the 4th quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company’s stock worth $1,791,000 after acquiring an additional 16 shares during the last quarter. Petros Family Wealth LLC boosted its stake in Thermo Fisher Scientific by 3.9% during the 4th quarter. Petros Family Wealth LLC now owns 456 shares of the medical research company’s stock valued at $264,000 after purchasing an additional 17 shares during the last quarter. Salomon & Ludwin LLC increased its holdings in shares of Thermo Fisher Scientific by 1.6% in the 4th quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company’s stock worth $669,000 after purchasing an additional 17 shares in the last quarter. Financial Management Network Inc. raised its stake in shares of Thermo Fisher Scientific by 3.7% in the third quarter. Financial Management Network Inc. now owns 511 shares of the medical research company’s stock worth $248,000 after purchasing an additional 18 shares during the last quarter. Finally, Pallas Capital Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 1.5% during the fourth quarter. Pallas Capital Advisors LLC now owns 1,256 shares of the medical research company’s stock valued at $728,000 after purchasing an additional 18 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $501.72 on Tuesday. Thermo Fisher Scientific has a 1 year low of $385.46 and a 1 year high of $643.99. The stock has a market capitalization of $186.38 billion, a P/E ratio of 28.28, a P/E/G ratio of 2.89 and a beta of 0.96. The company’s 50-day moving average is $567.28 and its 200 day moving average is $548.67. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, topping the consensus estimate of $6.45 by $0.12. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The business had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.95 billion. During the same period last year, the business posted $6.10 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 7.2% compared to the same quarter last year. On average, sell-side analysts expect that Thermo Fisher Scientific will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Friday, March 13th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Friday, March 13th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.70%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.